Hengrui makes headway with novel drugs but investors bide their time
A cancer drug developed by the Chinese firm has entered the European regulatory process and Novo Nordisk has bought rights to a potential weight-loss therapy Key Takeaways: Hengrui Pharma’s cancer…
Then there were two: BeOne moves beyond single-blockbuster dependence
The company’s Sonrotoclax is the first newly approved BCL-2 inhibitor in the U.S. in nearly a decade, giving BeOne a potential new hit beyond its Zanubrutinib blood cancer therapy Key…
Recent Articles
Hengrui makes headway with novel drugs but investors bide their time
1276.HK
600276.SHG
Then there were two: BeOne moves beyond single-blockbuster dependence
6160.HK
688235.SHG
ONC.US
RELATED ARTICLES
-
Drug spin-off trend gains traction with IPO by Hengrui offshoot
1276.HK600276.SHG - Hansoh’s overseas ambitions tested as EU stalls cancer drug sales
-
Can a novel sleeping pill help Jingxin shed its generic label?
002020.SHE
-
Cancer drug sales power up Kelun-Biotech’s profit engine
6990.HK
-
Salubris refiles for Hong Kong IPO as generics lose steam
002294.SHE
-
Drug setback leaves Ascletis with an all-in bet on weight loss
1672.HK
-
Then there were two: BeOne moves beyond single-blockbuster dependence
6160.HK688235.SHGONC.US
